The impact of the Oncotype DX® Recurrence Score® on treatment decisions in breast cancer patients

The impact of the Oncotype DX® Recurrence Score® on treatment decisions in breast cancer patients

EMJ

4 years
627 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The results of the Oncotype DX® Breast Cancer Assay are reported as a Recurrence Score® a number ranging from 0 to 100. This number indicates the likelihood that a woman's breast cancer will spread to another area of her body within 10 years of her initial diagnosis. The lower the score is, the lower the chances are that the woman's breast cancer will come back. The higher the score is, the greater the chances that the breast cancer will come back. Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses how the Recurrence Score result of the Oncotype DX assay could influence treatment decisions, especially in the intermediate Recurrence Score group. She confirms, from her experience, that the Oncotype DX Recurrence Score result reduces physicians' and patients' anxiety regarding their optimal treatment decisions. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay